TransMedics Group’s (TMDX) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $120.00 target price on the stock.

TMDX has been the topic of a number of other reports. Oppenheimer boosted their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an outperform rating in a research note on Wednesday, May 1st. TD Cowen boosted their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a buy rating in a research note on Friday, June 7th. Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an equal weight rating in a research note on Wednesday, February 28th. Stephens assumed coverage on TransMedics Group in a research note on Tuesday, June 4th. They set an overweight rating and a $151.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price target on TransMedics Group from $105.00 to $127.00 and gave the stock an overweight rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of Moderate Buy and a consensus price target of $133.88.

TransMedics Group Stock Down 3.4 %

Shares of TMDX opened at $139.04 on Friday. The company has a market capitalization of $4.58 billion, a PE ratio of -408.94 and a beta of 1.95. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $149.10. The stock’s 50-day moving average price is $125.30 and its two-hundred day moving average price is $96.72. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The firm’s revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS. On average, analysts anticipate that TransMedics Group will post 0.77 EPS for the current year.

Insiders Place Their Bets

In other news, Director David Weill sold 1,193 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the transaction, the director now directly owns 10,732 shares of the company’s stock, valued at $1,520,187.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director David Weill sold 1,193 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the transaction, the director now directly owns 10,732 shares of the company’s stock, valued at $1,520,187.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,744,059.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 290,501 shares of company stock valued at $33,268,189. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in TransMedics Group by 3.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 249,174 shares of the company’s stock valued at $13,642,000 after purchasing an additional 8,176 shares during the last quarter. HighTower Advisors LLC lifted its stake in TransMedics Group by 25.2% in the third quarter. HighTower Advisors LLC now owns 10,227 shares of the company’s stock valued at $553,000 after purchasing an additional 2,057 shares during the last quarter. Rhumbline Advisers lifted its stake in TransMedics Group by 2.5% in the third quarter. Rhumbline Advisers now owns 46,595 shares of the company’s stock valued at $2,551,000 after purchasing an additional 1,123 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in TransMedics Group in the third quarter valued at approximately $203,000. Finally, Envestnet Asset Management Inc. lifted its stake in TransMedics Group by 104.0% in the third quarter. Envestnet Asset Management Inc. now owns 80,752 shares of the company’s stock valued at $4,421,000 after purchasing an additional 41,168 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.